A primary objective in malaria vaccine design is the generation of high-quality antibody
responses against the circumsporozoite protein of the malaria parasite, Plasmodium …

Malaria, which is the result of Plasmodium falciparum infection, is a global health threat that
resulted in 655,000 deaths and 216 million clinical cases in 2010 alone. Recent phase 3 …

ABSTRACT A vaccine candidate that elicits humoral and cellular responses to multiple
sporozoite and liver-stage antigens may be able to confer protection against Plasmodium …

Immune response against circumsporozoite protein (CSP) of Plasmodium berghei, a major
surface protein on the sporozoite, confers protection in various murine malaria models …

The leading malaria vaccine candidate, RTS, S, based on the Plasmodium falciparum
circumsporozoite protein (CSP), will likely be the first publicly adopted malaria vaccine …

Plasmodium falciparum malaria remains the deadliest parasitic disease worldwide.
Vaccines targeting the preerythrocytic sporozoite and liver stages have the potential to …

Background Rodent malaria parasites where the gene encoding circumsporozoite protein
(CSP) has been replaced with csp genes from the human malaria parasites, Plasmodium …

Pfs25 is a malaria transmission-blocking vaccine antigen candidate, but its apparently
limited immunogenicity in humans has hindered clinical development. Here, we show that …

Epitopes of the circumsporozoite (CS) protein of Plasmodium falciparum, the most
pathogenic species of the malaria parasite, have been shown to elicit protective immunity in …

Due to the complex life cycle and high antigenic diversity of the malaria parasite, a
multistage vaccine may be necessary for optimal protection against the disease. Our …